Psychiatry and Neurology, Neurology · Oklahoma City, OK
NPI
1215969605
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
820 NE 15th St
Oklahoma City, OK, 73104
Phone (405) 271-6242
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
28,405 services
Medicare patients, 2024
169
Average age 65
Drug cost, 2024
$4.1M
2,410 prescriptions
Company payments, 2025
$315K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gabriel Pardo was code J2350 (injection, ocrelizumab, 1 mg), 25,800 times for 25 patients. In total Gabriel Pardo billed 28,405 services in 22 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-05-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 25,800 | 25 | $43.63 | $1.1M |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 896 | 28 | $0.21 | $189 |
| 99214 Office E&M - Established | Office | 170 | 153 | $78.72 | $13K |
| 96415 Chemotherapy Administration | Office | 58 | 29 | $18.60 | $1,079 |
| 96375 Injection Administration | Office | 53 | 28 | $9.27 | $491 |
| 96413 Chemotherapy Administration | Office | 53 | 30 | $86.17 | $4,567 |
| J2930 Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 12 | 12 | $3.07 | $36.88 |
By year: 2022 $1.1M for 27,039 services; 2023 $1.1M for 25,532 services; 2024 $1.2M for 28,405 services.
Medicare prescription drug claims, 2024
In 2024, the drug Gabriel Pardo prescribed most often to Medicare patients was Gabapentin, with 195 prescriptions and refills. In total Gabriel Pardo wrote 2,410 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 195 | 403 | 49 | $4,027 |
| Baclofen Generic | 162 | 314 | 36 | $5,640 |
| Clonazepam Generic | 146 | 173 | 24 | $620 |
| Modafinil Generic | 126 | 195 | 26 | $7,115 |
| Tizanidine Hcl Generic | 118 | 236 | 29 | $2,291 |
| Copaxone Glatiramer Acetate | 92 | 93 | Under 11 | $543K |
| Teriflunomide Generic | 83 | 87 | 13 | $61K |
| Duloxetine Hcl Generic | 71 | 171 | 17 | $1,421 |
| Pregabalin Generic | 64 | 96 | 15 | $3,820 |
| Dalfampridine Er Dalfampridine | 54 | 124 | 13 | $46K |
| Myrbetriq Mirabegron | 49 | 84 | 14 | $37K |
| Mayzent Siponimod | 44 | 50 | Under 11 | $494K |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | 44 | 44 | Under 11 | $2,807 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 44 | 76 | Under 11 | $593 |
| Tamsulosin Hcl Generic | 41 | 81 | Under 11 | $370 |
Brand drugs: 456 claims; generic drugs: 1,954 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gabriel Pardo $315K ($312K in general payments such as food, travel and fees and $3,275 for research) from 20 companies. The largest payer was EMD Serono, Inc. with $156K.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 98 | $156K |
| Genentech USA, Inc. ROG.SW | 58 | $59K |
| TG Therapeutics, Inc. TGTX | 66 | $51K |
| Genzyme Corporation SNY | 10 | $18K |
| Novartis Pharmaceuticals Corporation NVS | 32 | $13K |
| Amgen Inc. AMGN | 19 | $7,550 |
| Merck Healthcare KGaA | 1 | $6,300 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $2,443 |
| Biogen, Inc. BIIB | 13 | $545 |
| F. Hoffmann-La Roche AG ROG.SW | 1 | $306 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.